Maxigra (Sildenafil Citrate)

Sildenafil citrate selectively blocks phosphodiesterase type 5, an enzyme that degrades cyclic guanosine monophosphate (cGMP). By preserving cGMP, it promotes smooth‑muscle relaxation in the corpus cavernosum and pulmonary vessels, increasing blood flow to the penis or lungs.

The appropriate dose of Maxigra is determined by a qualified prescriber based on the individual’s medical condition, response to therapy, and any concomitant medications. Patients should follow the dosing instructions provided by their healthcare professional.

The safety of sildenafil citrate in pregnancy or while breastfeeding has not been established. It is generally not recommended for use in these populations unless the potential benefit justifies the potential risk, as assessed by a healthcare provider.

To order Maxigra, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Maxigra (sildenafil) shares the same mechanism as other PDE5 inhibitors such as tadalafil and vardenafil. Differences lie in onset of action, duration of effect, and dosing frequency. Sildenafil typically acts within 30‑60 minutes and lasts up to 4‑6 hours, whereas tadalafil may last up to 36 hours.

Maxigra tablets should be stored at ambient temperature, below 25 °C, in the original blister pack or container. Protect them from moisture, direct sunlight and excessive heat to maintain product stability throughout its shelf life.

Maxigra is taken orally, usually with water, about 30‑60 minutes before sexual activity for erectile dysfunction or as prescribed for pulmonary arterial hypertension. It may be taken with or without food, but a high‑fat meal can delay its onset.

Serious risks include priapism (a painful erection lasting more than four hours), sudden hearing loss, and rare cardiovascular events such as myocardial infarction or stroke, particularly in patients with pre‑existing heart disease. Immediate medical attention is required if these occur.

Maxigra should not be used by individuals taking nitrates, those with severe uncontrolled hypertension, recent history of stroke or heart attack, or patients with certain retinal disorders. Contra‑indications are determined by the prescribing clinician based on the patient’s overall health profile.